Metabolic confirms dosing study
Tuesday, 08 March, 2005
Metabolic Pharmaceuticals (ASX:MBP) has confirmed that it will perform a further dosing study of its anti-obesity drug AOD9604, but a final decision on the protocol must await the outcome of partnering discussions
Analysis of the results from last year's Phase IIb study suggested that the optimal dosage was potentially below the lowest dose of 1 mg used in the trial, and the company is expecting to commence a dosage study looking at dosages below this level in the third quarter this year.
The trial is also likely to address the issue of whether weight loss continues at the same rate past 12 weeks.
According to a company update released today, the final protocol for the study will depend on whether Metabolic has partnered with a pharmaceutical company prior to the trial commencing. The company is currently in discussions with several pharma companies and has said that data packages from the Phase IIb trial have been requested by more than ten companies since the completion of the trial.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
